MCID: FBR017
MIFTS: 61

Fibrosarcoma

Categories: Rare diseases, Cancer diseases, Bone diseases

Aliases & Classifications for Fibrosarcoma

MalaCards integrated aliases for Fibrosarcoma:

Name: Fibrosarcoma 12 72 49 55 28 51 41 14 69
Neoplasms, Fibrous Tissue 41 69
Fibrosarcoma of Soft Tissue 12
Fibrous Tissue Neoplasm 12
Fibrocytic Tumor 12

Characteristics:

Orphanet epidemiological data:

55
fibrosarcoma
Prevalence: <1/1000000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 55  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:3355
SNOMED-CT 64 443250000 53654007
Orphanet 55 ORPHA2030
MESH via Orphanet 42 D005354
UMLS via Orphanet 70 C0016057
ICD10 via Orphanet 33 C49.9

Summaries for Fibrosarcoma

Disease Ontology : 12 A connective tissue cancer that has material basis in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern.

MalaCards based summary : Fibrosarcoma, also known as neoplasms, fibrous tissue, is related to pediatric fibrosarcoma and breast adenocarcinoma. An important gene associated with Fibrosarcoma is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Integrin Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Tamoxifen and Menthol have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and bone marrow, and related phenotypes are shRNA abundance <= 50% and growth/size/body region

Wikipedia : 72 Fibrosarcoma (fibroblastic sarcoma) is a malignant mesenchymal tumour derived from fibrous connective... more...

Related Diseases for Fibrosarcoma

Diseases in the Fibrosarcoma family:

Adult Fibrosarcoma Congenital Fibrosarcoma

Diseases related to Fibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 pediatric fibrosarcoma 33.7 ETV6 NTRK3
2 breast adenocarcinoma 30.0 MMP9 PLAU TNF
3 aortic aneurysm 30.0 MMP2 MMP9 TIMP1
4 aortic aneurysm, familial abdominal, 1 29.4 MMP1 MMP14 MMP2 MMP9 PLAU TIMP1
5 small bowel fibrosarcoma 12.1
6 liver fibrosarcoma 12.1
7 congenital fibrosarcoma 12.1
8 heart fibrosarcoma 12.1
9 breast fibrosarcoma 12.1
10 fibrosarcoma of bone 12.1
11 adult fibrosarcoma 12.0
12 central nervous system fibrosarcoma 12.0
13 kidney fibrosarcoma 11.9
14 conventional fibrosarcoma 11.9
15 dermatofibrosarcoma protuberans 11.4
16 desmoid tumor 11.3
17 infantile myofibromatosis 11.2
18 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.2
19 inflammatory myofibroblastic tumor 11.2
20 extracranial arteriovenous malformation 10.7 MMP2 MMP9
21 adult mesoblastic nephroma 10.7 ETV6 NTRK3
22 focal myositis 10.7 MMP2 MMP9
23 amaurosis fugax 10.6 MMP9 SERPINE1
24 lentigo maligna melanoma 10.6 MMP2 MMP9
25 conjunctival nevus 10.6 MMP2 MMP9 TIMP1
26 spastic entropion 10.6 MMP1 MMP2 MMP9
27 lung giant cell carcinoma 10.6 MMP2 MMP9 TIMP1
28 internal hemorrhoid 10.6 MMP1 MMP2 MMP9
29 odontogenic myxoma 10.6 MMP1 MMP2 MMP9
30 klatskin's tumor 10.6 MMP14 MMP2 MMP9
31 villous adenocarcinoma 10.6 MMP2 MMP9
32 pelvic organ prolapse 10.6 MMP1 MMP2 MMP9
33 chronic venous leg ulcers 10.6 MMP9 TIMP1
34 hypertensive heart disease 10.6 MMP1 MMP2 MMP9
35 aortic aneurysm, familial thoracic 1 10.6 MMP1 MMP2 MMP9
36 multicentric osteolysis, nodulosis, and arthropathy 10.6 MMP14 MMP2
37 winchester syndrome 10.5 MMP14 MMP2
38 chronic venous insufficiency 10.5 MMP1 SERPINE1 TIMP1
39 venous insufficiency 10.5 MMP1 SERPINE1 TIMP1
40 carotid artery disease 10.5 MMP1 MMP9 TIMP1
41 chronic actinic dermatitis 10.5 MMP1 MMP9
42 transverse myelitis 10.5 MMP2 MMP9 TNF
43 psammomatous meningioma 10.5 MMP2 MMP9
44 gingival fibromatosis 10.5 MMP1 MMP2 TIMP1
45 appendicitis 10.5 MMP9 TIMP1 TNF
46 lymphangioleiomyomatosis 10.5 MMP1 MMP14 MMP2
47 joint disorders 10.5 PLAU TIMP1 TNF
48 bronchiolitis obliterans 10.5 MMP9 TIMP1 TNF
49 carotid stenosis 10.4 MMP1 MMP9 TNF
50 light chain deposition disease 10.4 MMP1 MMP14 MMP2 MMP9

Graphical network of the top 20 diseases related to Fibrosarcoma:



Diseases related to Fibrosarcoma

Symptoms & Phenotypes for Fibrosarcoma

GenomeRNAi Phenotypes related to Fibrosarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.36 ETV6 JUN MAF MAFB MAFF MAFG

MGI Mouse Phenotypes related to Fibrosarcoma:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 TNF JUN ETV6 MAF JAK1 MAFA
2 immune system MP:0005387 10.38 TNF ETV6 MAF JAK1 JUN MAFB
3 cardiovascular system MP:0005385 10.37 TIMP2 TNF JUN MAFB ETV6 JAK1
4 homeostasis/metabolism MP:0005376 10.37 TIMP2 TNF JUN ETV6 MAF JAK1
5 behavior/neurological MP:0005386 10.35 TIMP2 TNF JUN MAF JAK1 MAFB
6 hematopoietic system MP:0005397 10.32 TIMP2 TNF JUN ETV6 JAK1 MMP14
7 mortality/aging MP:0010768 10.31 TNF JUN ETV6 MAF JAK1 MAFB
8 endocrine/exocrine gland MP:0005379 10.19 TNF JUN ETV6 JAK1 MAFA MAFB
9 nervous system MP:0003631 10.15 TIMP2 TNF JUN MAF MAFB MMP14
10 integument MP:0010771 10.11 TNF JUN ETV6 MAF JAK1 MMP14
11 craniofacial MP:0005382 10.09 TNF MAF JAK1 MAFB MMP14 MMP2
12 normal MP:0002873 10.02 TIMP2 JUN ETV6 JAK1 MAFA MAFB
13 neoplasm MP:0002006 10.01 TNF ETV6 MMP2 MMP1 PLAU MMP9
14 respiratory system MP:0005388 9.9 TNF MAFB JAK1 JUN MMP14 MMP9
15 renal/urinary system MP:0005367 9.8 MAF JAK1 MAFA MAFB MMP14 MMP9
16 skeleton MP:0005390 9.61 TNF JUN JAK1 MAFB MMP14 MMP2
17 vision/eye MP:0005391 9.23 TNF JUN MAF MMP14 MMP2 PLAU

Drugs & Therapeutics for Fibrosarcoma

Drugs for Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
2
Menthol Approved Phase 4 2216-51-5 16666
3 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1,Not Applicable
4 Bone Density Conservation Agents Phase 4,Phase 2,Phase 1
5 Estrogen Receptor Modulators Phase 4,Phase 2,Phase 1
6 Estrogens Phase 4,Phase 2,Phase 1,Not Applicable
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Selective Estrogen Receptor Modulators Phase 4,Phase 2,Phase 1
11 Analgesics Phase 4,Phase 2,Phase 1
12 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1
13 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 1
15 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
16 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Dermatologic Agents Phase 4,Phase 3,Phase 2
18 Efamol Phase 4
19 Estrogen Antagonists Phase 4,Phase 2,Phase 1
20 Hypolipidemic Agents Phase 4
21 Lipid Regulating Agents Phase 4
22 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable
23 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
24 Anesthetics, Local Phase 4,Phase 3,Phase 2
25 Evening Primrose Nutraceutical Phase 4
26
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
27
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
28
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
29
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
30
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
31
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
32
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
33
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
34
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
35
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
36
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
37
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
38
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
39
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
40
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
41
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
42
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
43
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
44
Cyproheptadine Approved Phase 3 129-03-3 2913
45
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
46
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4 445354
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
48
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
49
Nicotinamide Approved, Investigational, Nutraceutical Phase 3,Phase 2 98-92-0 936
50
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032

Interventional clinical trials:

(show top 50) (show all 248)

# Name Status NCT ID Phase Drugs
1 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
2 Retreatment of Recurrent Dupuytren's Contractures Completed NCT01498640 Phase 4
3 MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex Completed NCT01450397 Phase 4
4 Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb Completed NCT01265420 Phase 4
5 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
6 Trial Comparing Treatment Strategies in Dupuytren's Contracture Recruiting NCT03192020 Phase 4 Collagenase Clostridium Histolyticum 2.9 MG/ML [Xiaflex]
7 Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease Recruiting NCT03000114 Phase 4 XIAFLEX
8 Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture Recruiting NCT02476461 Phase 4 xiapex
9 Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF Active, not recruiting NCT02647619 Phase 4 Xiapex
10 Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease Enrolling by invitation NCT03406338 Phase 4 Collagenase Clostridium Histolyticum
11 Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture Terminated NCT01226121 Phase 4
12 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
13 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
14 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
15 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
16 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
17 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
18 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
19 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
20 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
21 Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU) Completed NCT02011919 Phase 2, Phase 3
22 Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease Completed NCT00533273 Phase 3
23 Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease Completed NCT00528840 Phase 3
24 AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease Completed NCT00528424 Phase 3
25 Collagenase in the Treatment of Dupuytrens Disease Completed NCT00260429 Phase 3
26 Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures Completed NCT01674634 Phase 3
27 Collagenase Option for Reduction of Dupuytren's Contracture in Japan Completed NCT01588353 Phase 3 Collagenase Clostridium Histolyticum
28 Administration of Two Injections for Multiple Dupuytren's Contractures Completed NCT01407068 Phase 3
29 Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex) Completed NCT01229436 Phase 3 Xiapex
30 Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing Completed NCT00931567 Phase 2, Phase 3
31 Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture Completed NCT00565019 Phase 3 Triamcinolone Acetonide
32 AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture Completed NCT00528606 Phase 3
33 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
34 Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease Completed NCT00014742 Phase 3 collagenase
35 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
36 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
37 Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's Recruiting NCT02725528 Phase 3 collagenase injection
38 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
39 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
40 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Active, not recruiting NCT02066181 Phase 3 Sorafenib Tosylate
41 Feasibility Study Assessing the Treatment of Fibroadenomata With a Circumferential Sonication Treatment With HIFU Active, not recruiting NCT02139683 Phase 3
42 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
43 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
44 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
45 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
46 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
47 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
48 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
49 MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas Terminated NCT00147108 Phase 3
50 Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease Withdrawn NCT01776892 Phase 3 Collegenase injection

Search NIH Clinical Center for Fibrosarcoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: fibrosarcoma

Genetic Tests for Fibrosarcoma

Genetic tests related to Fibrosarcoma:

# Genetic test Affiliating Genes
1 Fibrosarcoma 28

Anatomical Context for Fibrosarcoma

MalaCards organs/tissues related to Fibrosarcoma:

38
Bone, Lung, Bone Marrow, Liver, Colon, Heart, T Cells

Publications for Fibrosarcoma

Articles related to Fibrosarcoma:

(show top 50) (show all 926)
# Title Authors Year
1
Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity. ( 29250984 )
2018
2
Development of Orally Applicable, Combinatorial Drug-Loaded Nanoparticles for the Treatment of Fibrosarcoma. ( 29339136 )
2018
3
ADAMTS-1 disrupts HGF/c-MET signaling and HGF-stimulated cellular processes in fibrosarcoma. ( 29355494 )
2018
4
Solubilization of a Poorly Soluble B-Raf (Rapidly Accelerated Fibrosarcoma) Inhibitor: From Theory to Application. ( 28989016 )
2018
5
Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma. ( 29430000 )
2018
6
Primary Renal Hybrid Low-grade Fibromyxoid Sarcoma-Sclerosing Epithelioid Fibrosarcoma: An Unusual Pediatric Case With EWSR1-CREB3L1 Fusion. ( 29426275 )
2018
7
Fibrosarcoma of the eyelid in two sibling Czech wolfdogs. ( 28616389 )
2017
8
Effect of TERT on the growth of fibrosarcoma via caspase-3, survivin and PKB. ( 28789428 )
2017
9
Destructive Fibrosarcoma of the Maxillary Sinus. ( 29283942 )
2017
10
Effect of metformin on fibrosarcoma in hamsters. ( 29243803 )
2017
11
MicroRNA-29 Family Suppresses the Invasion of HT1080 Human Fibrosarcoma Cells by Regulating Matrix Metalloproteinase 2 Expression. ( 28584796 )
2017
12
Spontaneous Regression in a Patient With Infantile Fibrosarcoma. ( 29200168 )
2017
13
A delayed presentation of ameloblastic fibrosarcoma in an African patient. ( 28765185 )
2017
14
Primary sclerosing epithelioid fibrosarcoma of the pleura. ( 29340499 )
2017
15
Photodynamic therapy in fibrosarcoma BALB/c animal model: Observation of the rebound effect. ( 29155337 )
2017
16
Primary Central Nervous System Fibrosarcoma. ( 28936084 )
2017
17
IGF-I regulates HT1080 fibrosarcoma cell migration through a syndecan-2/Erk/ezrin signaling axis. ( 28962916 )
2017
18
Congenital Infantile Fibrosarcoma in the Premature Infant. ( 29099410 )
2017
19
Sclerosing Epithelioid Fibrosarcoma of the Jaw: Late Recurrence from a Low Grade Fibromyxoid Sarcoma. ( 29274042 )
2017
20
Korean Sa-Ahm Acupuncture for Treating Canine Oral Fibrosarcoma. ( 28712481 )
2017
21
Metastatic Sclerosing Epithelioid Fibrosarcoma in Bone Marrow. ( 28697683 )
2017
22
Induction of antitumor response to fibrosarcoma by Newcastle disease virus-infected tumor vaccine. ( 28864944 )
2017
23
Enhanced cellular functions through induction of LPA2 by cisplatin in fibrosarcoma HT1080 cells. ( 28205098 )
2017
24
Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. ( 28877062 )
2017
25
A novel EWS-CREB3L3 gene fusion in a mesenteric sclerosing epithelioid fibrosarcoma. ( 28569045 )
2017
26
Primary fibrosarcoma of the urinary bladder in a cat: follow-up after incomplete surgical excision. ( 28680699 )
2017
27
LipodoxAr (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus CaelyxAr (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models. ( 28587612 )
2017
28
Congenital infantile fibrosarcoma mimicking a cutaneous vascular lesion: a case report and review of the literature. ( 27910123 )
2017
29
Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells. ( 28578659 )
2017
30
Congenital Infantile Fibrosarcoma Causing Intestinal Perforation in a Newborn. ( 28690909 )
2017
31
Evaluation of fluorescence-guided surgery agents in a murine model of soft tissue fibrosarcoma. ( 29284070 )
2017
32
Ameloblastic fibroma and ameloblastic fibrosarcoma: A systematic review. ( 28776760 )
2017
33
Harnessing the heart's resistance to malignant tumors: cardiac-derived extracellular vesicles decrease fibrosarcoma growth and leukemia-related mortality in rodents. ( 29245929 )
2017
34
In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets. ( 28939748 )
2017
35
Macrophage cell-derived exosomes/staphylococcal enterotoxin B against fibrosarcoma tumor. ( 28843722 )
2017
36
The effects of gene therapy with granulocyte-macrophage colony-stimulating factor in the regression of tumor masses in fibrosarcoma mouse model. ( 28643761 )
2017
37
Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies. ( 29262667 )
2017
38
Inhibitory Effect of<i>Hizikia fusiformis</i>Solvent-Partitioned Fractions on Invasion and MMP Activity of HT1080 Human Fibrosarcoma Cells. ( 29043215 )
2017
39
A meningeal fibrosarcoma on the same site of osteodural decompression: a pure coincidence? ( 28643506 )
2017
40
Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. ( 29099503 )
2017
41
Analysis of infantile fibrosarcoma reveals extensive T-cell responses within tumors: Implications for immunotherapy. ( 28921877 )
2017
42
A Case of Congenital Infantile Fibrosarcoma of the Bowel Presenting as a Neonatal Intussusception. ( 29090505 )
2017
43
Sclerosing epithelioid fibrosarcoma. ( 27631873 )
2016
44
Mechanistic investigation of toxicity of chromium oxide nanoparticles in murine fibrosarcoma cells. ( 27099490 )
2016
45
Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. ( 26563356 )
2016
46
Rare Undifferentiated Tumour of Thyroid: Primary Thyroid Fibrosarcoma. ( 27504356 )
2016
47
Corneal fibrosarcoma in a cat. ( 26840792 )
2016
48
Novel Antitumor Invasive Actions of p-Cymene by Decreasing MMP-9/TIMP-1 Expression Ratio in Human Fibrosarcoma HT-1080 Cells. ( 27476935 )
2016
49
Evaluation of (188)Re-labeled NGR-VEGI protein for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts. ( 26768609 )
2016
50
Infantile Fibrosarcoma of Tongue: A Rare Tumor. ( 27398324 )
2016

Variations for Fibrosarcoma

Expression for Fibrosarcoma

Search GEO for disease gene expression data for Fibrosarcoma.

Pathways for Fibrosarcoma

Pathways related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.31 JAK1 JUN MMP1 MMP2 MMP9 PLAU
2
Show member pathways
13.29 JAK1 MAFF MAFG MAFK MMP1 PLAU
3 12.81 JAK1 JUN MMP1 MMP2 MMP9
4
Show member pathways
12.66 MMP1 MMP14 MMP2 MMP9 SERPINE1 TIMP1
5
Show member pathways
12.28 JAK1 JUN MMP1 MMP9 TNF
6 12.27 MMP2 MMP9 PLAU TNF
7 12.23 ETV6 MAF MMP9 PLAU
8
Show member pathways
12.23 JAK1 JUN MMP1 SERPINE1 TIMP1
9 12.13 JAK1 MMP1 MMP14 MMP2 MMP9 TNF
10 12.07 JUN MMP2 MMP9 TNF
11 12 MMP14 MMP2 MMP9 SERPINE1
12 11.93 JUN MMP14 MMP9 TNF
13 11.92 JUN MMP14 PLAU SERPINE1
14 11.88 JUN MMP2 SERPINE1 TNF
15 11.86 JAK1 MMP1 MMP2 MMP9 TIMP1 TNF
16 11.82 JUN MMP1 TNF
17 11.8 MMP2 MMP9 TIMP1 TIMP2
18
Show member pathways
11.79 JAK1 JUN TIMP1
19 11.75 JUN MMP2 MMP9
20
Show member pathways
11.75 MMP1 MMP14 MMP2 MMP9 TFPI2 TIMP1
21
Show member pathways
11.73 JUN MAF TNF
22 11.71 MMP1 MMP2 MMP9
23 11.65 JUN MMP2 MMP9
24 11.64 JUN MMP14 MMP2 MMP9
25
Show member pathways
11.6 JAK1 JUN MMP2 MMP9
26 11.6 MMP2 MMP9 PLAU TIMP1 TNF
27 11.57 JUN MMP2 PLAU
28 11.57 JAK1 JUN SERPINE1 TNF
29
Show member pathways
11.57 JUN MMP1 MMP2 MMP9 TNF
30 11.53 JAK1 JUN MMP1
31 11.53 JUN MMP2 TNF
32 11.51 JAK1 TIMP1 TNF
33 11.49 JUN MMP9 PLAU
34 11.48 MMP2 MMP9 PLAU TNF
35
Show member pathways
11.43 JUN MMP2 MMP9 PLAU
36 11.39 MMP1 MMP9 TIMP2
37 11.19 JUN MMP1 MMP2 MMP9 PLAU
38 11.14 MMP9 TIMP1 TIMP2
39 11.14 JUN MAF MAFA MAFB MAFF MAFG
40 11.01 MMP1 MMP14 MMP2 MMP9 PLAU SERPINE1
41 10.99 JUN NTRK3 TIMP1 TIMP2 TNF
42 10.99 JAK1 MMP1 TIMP1
43 10.8 PLAU SERPINE1

GO Terms for Fibrosarcoma

Cellular components related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 MMP1 MMP2 MMP9 PLAU SERPINE1 TFPI2
2 extracellular space GO:0005615 9.76 MMP14 MMP2 MMP9 PLAU SERPINE1 TIMP1
3 proteinaceous extracellular matrix GO:0005578 9.43 MMP1 MMP2 MMP9 TFPI2 TIMP1 TIMP2
4 extracellular matrix GO:0031012 9.23 MMP1 MMP14 MMP2 MMP9 SERPINE1 TFPI2

Biological processes related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.87 JUN MMP14 MMP2 SERPINE1
2 positive regulation of cell migration GO:0030335 9.85 MMP14 MMP9 NTRK3 PLAU
3 negative regulation of endopeptidase activity GO:0010951 9.8 SERPINE1 TFPI2 TIMP1 TIMP2
4 regulation of cell proliferation GO:0042127 9.8 JAK1 JUN MAFG PLAU TNF
5 transcription by RNA polymerase II GO:0006366 9.8 ETV6 JUN MAF MAFA MAFB MAFF
6 negative regulation of peptidase activity GO:0010466 9.78 SERPINE1 TFPI2 TIMP1 TIMP2
7 response to organic substance GO:0010033 9.77 JUN TIMP1 TNF
8 circadian rhythm GO:0007623 9.77 JUN NTRK3 SERPINE1
9 ephrin receptor signaling pathway GO:0048013 9.75 MMP2 MMP9 NTRK3
10 blood coagulation GO:0007596 9.72 MAFF MAFG MAFK PLAU TFPI2
11 response to cytokine GO:0034097 9.71 JUN TIMP1 TIMP2
12 response to hormone GO:0009725 9.7 MMP14 TIMP1 TIMP2
13 endodermal cell differentiation GO:0035987 9.61 MMP14 MMP2 MMP9
14 positive regulation of transcription by RNA polymerase II GO:0045944 9.61 ETV6 JUN MAF MAFA MAFB MAFF
15 lens fiber cell differentiation GO:0070306 9.58 MAF NTRK3
16 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.56 TIMP1 TIMP2
17 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.54 MMP2 MMP9 TNF
18 negative regulation of metallopeptidase activity GO:1905049 9.51 TIMP1 TIMP2
19 regulation of epidermal cell differentiation GO:0045604 9.46 MAFF MAFG
20 collagen catabolic process GO:0030574 9.46 MMP1 MMP14 MMP2 MMP9
21 extracellular matrix disassembly GO:0022617 9.1 MMP1 MMP14 MMP2 MMP9 TIMP1 TIMP2

Molecular functions related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.95 MMP1 MMP14 MMP2 MMP9 TIMP1 TIMP2
2 peptidase activity GO:0008233 9.89 MMP1 MMP14 MMP2 MMP9 PLAU
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.83 ETV6 JUN MAFA MAFB MAFG
4 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.72 ETV6 JUN MAFA MAFB MAFG
5 metallopeptidase activity GO:0008237 9.71 MMP1 MMP14 MMP2 MMP9
6 peptidase inhibitor activity GO:0030414 9.67 SERPINE1 TFPI2 TIMP1 TIMP2
7 metalloendopeptidase activity GO:0004222 9.56 MMP1 MMP14 MMP2 MMP9
8 serine-type endopeptidase activity GO:0004252 9.55 MMP1 MMP14 MMP2 MMP9 PLAU
9 metalloendopeptidase inhibitor activity GO:0008191 9.51 TIMP1 TIMP2
10 protease binding GO:0002020 9.26 SERPINE1 TIMP1 TIMP2 TNF
11 DNA binding transcription factor activity GO:0003700 9.23 ETV6 JUN MAF MAFA MAFB MAFF
12 protein binding GO:0005515 10.39 ETV6 JAK1 JUN MAF MAFB MAFF

Sources for Fibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....